The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

This preferential treatment harms independent pharmacies and ... there has traditionally been a lack of uptake in biosimilars on PBM formularies, likely due to less favorable PBM rebate models ...

Low-level laser therapy is a non-invasive treatment for TMJ symptoms that uses light to stimulate cellular activity, and it's ...

Based on conversations with industry expects, the Act, while incremental, does not include any adverse new ideas that would materially harm PBM profits, and the text allows enough room and time ...

Ron Wyden says Elon Musk, an advisor to President Donald Trump who's on track to lead a new Department of Government Efficiency, pushed the PBM provisions out of the package. The new American ...

As the middlemen between drug companies and insurers, PBMs are shoo-ins as the villains behind high drug prices. But they do ...

The PBM changes would put guardrails on the business practices of the industry, something that’s been a bipartisan priority for years but, until now, never made it to the finish. The package ...

"They're helping patients kind of manage through the treatment paradigm with respect to which drugs to take, which formulary drugs are on, and kind of managing that whole process. So there is a ...